Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu Province, China.
Clin Chim Acta. 2010 Jan;411(1-2):26-30. doi: 10.1016/j.cca.2009.09.033. Epub 2009 Oct 3.
Visfatin is a newly identified pro-inflammatory adipokine expressed predominantly in visceral fat. Previous studies have suggested a role for visfatin in low-grade inflammation and regulation of lipid metabolism. Most recently, a genetic polymorphism -1535C>T located in the visfatin gene promoter has been identified, and suggested to be associated with the regulation of visfatin expression, lipid levels. However, it is unclear whether this polymorphism has a linkage with CAD.
We conducted a hospital-based case-control study with 257 CAD patients and 292 controls to examine the potential association of the Visfatin -1535C>T polymorphism with CAD.
The frequencies of the CC, CT, and TT genotypes in cases were significantly different from those of controls (chi2=6.223, P=0.045). Subjects with the variant genotypes (CT+TT) had a 40% decreased risk of CAD relative to CC carriers (adjusted OR=0.60, 95%CI=0.40-0.89). Furthermore, the adjusted OR of a TT genotype for CAD was 0.52 (95%CI=0.31-0.87). There was a significant association between Visfatin -1535C>T polymorphism and triglyceride levels in both CAD patients and controls (P=0.003, 0.018, respectively). In stratified analyses, the T allele was significantly associated with reduced risk of CAD in males, subjects with age <59years, and non-smokers. Moreover, a borderline statistical significance (P=0.058 for trend) was observed between the variant genotypes and severity of CAD.
Our results suggested that Visfatin -1535C>T polymorphism might be associated with reduced risk of CAD in a Chinese population.
内脏脂肪素是一种新发现的促炎脂肪因子，主要在内脏脂肪中表达。先前的研究表明，内脏脂肪素在低度炎症和脂质代谢调节中起作用。最近，在脂肪因子基因启动子中发现了一种遗传多态性-1535C>T，并且该多态性与内脏脂肪素的表达、脂质水平的调节有关。然而，这种多态性是否与 CAD 有关尚不清楚。
我们进行了一项以医院为基础的病例对照研究，共纳入 257 例 CAD 患者和 292 例对照，以检验 Visfatin-1535C>T 多态性与 CAD 之间的潜在关联。
病例组 CC、CT 和 TT 基因型的频率明显不同于对照组（chi2=6.223，P=0.045）。与 CC 携带者相比，携带变异基因型（CT+TT）的个体 CAD 的风险降低了 40%（调整 OR=0.60，95%CI=0.40-0.89）。此外，TT 基因型患 CAD 的调整 OR 为 0.52（95%CI=0.31-0.87）。在 CAD 患者和对照组中，Visfatin-1535C>T 多态性与甘油三酯水平之间均存在显著关联（分别为 P=0.003、0.018）。在分层分析中，T 等位基因与男性、年龄<59 岁和非吸烟者 CAD 风险降低显著相关。此外，在变异基因型与 CAD 严重程度之间还观察到了一个边缘统计学意义（趋势 P=0.058）。
我们的结果表明，在中国人群中，Visfatin-1535C>T 多态性可能与 CAD 风险降低有关。
